GSK (GSK) issued a statement disagreeing with the ruling by a state court in Delaware to allow jury trials for cases, which claim GSK's discontinued heartburn drug Zantac (ranitidine) causes cancer. The court's decision will allow 72,000 personal injury lawsuits filed in Delaware court to move forward to trial and expert witnesses to testify in court that Zantac may cause cancer. GSK shares declined more than 7% in pre-market trading on Monday in response to the legal setback. If the claims are proved in co ...